MA

Mark A. Goldsmith

Founding President & Chief Executive Officer at Revolution Medicines

San Francisco, US

About

Mark Goldsmith joined Third Rock Ventures in 2012. He serves as a Partner to the firm and participates in the ideation, development and leadership of new companies. Prior to joining Third Rock, Mark was President and Chief Executive Officer of Constellation Pharmaceuticals, the leading biopharmaceutical company in the field of epigenetics and a Third Rock Ventures portfolio company. Mark continues his active involvement with Constellation Pharmaceuticals by serving as Executive Chairman. Before Constellation, Mark held senior executive positions in the biotechnology industry and academia. Prior to his appointment at Constellation in 2009, Mark was a Senior Executive-in-Residence at Prospect Venture Partners, a leading healthcare venture capital firm. Previously, he served as CEO of Cogentus Pharmaceuticals and as Senior Vice President leading the health care division of Genencor International. Before entering the private sector, Mark led a medical research laboratory at the Gladsto

Position in the VCSift Database

  • 1 investors hold the Founding President & Chief Executive Officer role in VCSift. Mark A. Goldsmith is one of them.
  • 7,285 investors are based in San Francisco, California, United States.

Data sourced from 410,343 investor profiles. Updated July 2026.

Investment Focus

Contact Information

em••••@example.com
linkedin.com/in/••••••••

Unlock contact details with a VCSift subscription

Unlock Contact

Already subscribed? Log in

Find more investors like Mark

Search Investors